430 related articles for article (PubMed ID: 16708731)
1. An open label comparative study of glimepiride versus repaglinide in type 2 diabetes mellitus Muslim subjects during the month of Ramadan.
Anwar A; Azmi KN; Hamidon BB; Khalid BA
Med J Malaysia; 2006 Mar; 61(1):28-35. PubMed ID: 16708731
[TBL] [Abstract][Full Text] [Related]
2. Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan.
Bakiner O; Ertorer ME; Bozkirli E; Tutuncu NB; Demirag NG
Acta Diabetol; 2009 Mar; 46(1):63-5. PubMed ID: 18825302
[TBL] [Abstract][Full Text] [Related]
3. Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting.
Mafauzy M
Diabetes Res Clin Pract; 2002 Oct; 58(1):45-53. PubMed ID: 12161056
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
5. Clinical experience with repaglinide in patients with non-insulin-dependent diabetes mellitus.
Shapiro MS; Abrams Z; Lieberman N
Isr Med Assoc J; 2005 Feb; 7(2):75-7. PubMed ID: 15729954
[TBL] [Abstract][Full Text] [Related]
6. A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting.
Cesur M; Corapcioglu D; Gursoy A; Gonen S; Ozduman M; Emral R; Uysal AR; Tonyukuk V; Yilmaz AE; Bayram F; Kamel N
Diabetes Res Clin Pract; 2007 Feb; 75(2):141-7. PubMed ID: 16815586
[TBL] [Abstract][Full Text] [Related]
7. The effects of diet, sulfonylurea, and Repaglinide therapy on clinical and metabolic parameters in type 2 diabetic patients during Ramadan.
Sari R; Balci MK; Akbas SH; Avci B
Endocr Res; 2004 May; 30(2):169-77. PubMed ID: 15473127
[TBL] [Abstract][Full Text] [Related]
8. Sulphonylureas in the management of type 2 diabetes during the fasting month of Ramadan.
Zargar A; Basit A; Mahtab H
J Indian Med Assoc; 2005 Aug; 103(8):444-6. PubMed ID: 16363203
[TBL] [Abstract][Full Text] [Related]
9. Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide.
Yngen M; Ostenson CG; Hjemdahl P; Wallén NH
Diabet Med; 2006 Feb; 23(2):134-40. PubMed ID: 16433710
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.
Hassanein M; Hanif W; Malik W; Kamal A; Geransar P; Lister N; Andrews C; Barnett A
Curr Med Res Opin; 2011 Jul; 27(7):1367-74. PubMed ID: 21568833
[TBL] [Abstract][Full Text] [Related]
11. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study.
Aravind SR; Ismail SB; Balamurugan R; Gupta JB; Wadhwa T; Loh SM; Suryawanshi S; Davies MJ; Girman CJ; Katzeff HL; Radican L; Engel SS; Wolthers T
Curr Med Res Opin; 2012 Aug; 28(8):1289-96. PubMed ID: 22738801
[TBL] [Abstract][Full Text] [Related]
12. Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study.
Aravind SR; Al Tayeb K; Ismail SB; Shehadeh N; Kaddaha G; Liu R; Balshaw R; Lesnikova N; Heisel O; Girman CJ; Musser BJ; Davies MJ; Katzeff HL; Engel SS; Radican L;
Curr Med Res Opin; 2011 Jun; 27(6):1237-42. PubMed ID: 21506631
[TBL] [Abstract][Full Text] [Related]
13. Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.
Owens DR
Diabet Med; 1998; 15 Suppl 4():S28-36. PubMed ID: 9868989
[TBL] [Abstract][Full Text] [Related]
14. Suggested insulin regimens for patients with type 1 diabetes mellitus who wish to fast during the month of Ramadan.
Kobeissy A; Zantout MS; Azar ST
Clin Ther; 2008 Aug; 30(8):1408-15. PubMed ID: 18803984
[TBL] [Abstract][Full Text] [Related]
15. Repaglinide in combination therapy.
Moses R
Diabetes Nutr Metab; 2002 Dec; 15(6 Suppl):33-8. PubMed ID: 12702006
[TBL] [Abstract][Full Text] [Related]
16. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors.
Derosa G; Mugellini A; Ciccarelli L; Crescenzi G; Fogari R
Clin Ther; 2003 Feb; 25(2):472-84. PubMed ID: 12749508
[TBL] [Abstract][Full Text] [Related]
17. [Continuous glucose monitoring in glimipiride plus metformin treated type 2 diabetic patients during the month of Ramadan].
Oueslati I; Ben Said R; Kammoun I; Haouat E; Ben Salem L; Turki Z; Ben Slama C
Tunis Med; 2012 Oct; 90(10):735-9. PubMed ID: 23096516
[TBL] [Abstract][Full Text] [Related]
18. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes?
Nattrass M; Lauritzen T
Int J Obes Relat Metab Disord; 2000 Sep; 24 Suppl 3():S21-31. PubMed ID: 11063281
[TBL] [Abstract][Full Text] [Related]
19. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
20. Maintenance of glycaemic control with the evening administration of a long acting sulphonylurea in male type 2 diabetic patients undertaking the Ramadan fast.
Zargar AH; Siraj M; Jawa AA; Hasan M; Mahtab H
Int J Clin Pract; 2010 Jul; 64(8):1090-4. PubMed ID: 20455956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
